marketing@medicilon.com
PROTACs offer a fast and reversible chemical knock-down approach to control protein function. The impact of PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers an array of popular target protein ligands. We have established a linker system with an extensive collection of bifunctional linkers.Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize a substantial number of highly active PROTAC bispecific small molecules, with the potential to significantly facilitate the drug discovery and development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support.Learn more:PROTAC Drug Discovery Research Platform
In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers.Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of the end of 2023, Medicilon has successfully assisted 24 ADC drugs to obtain clinical approval, and more than 20 ADC projects are in development.Learn more:ADC R&D Service PlatformMedicilon nucleic acid drug R&D platform provides an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Oriented with a rigorous scientific approach, an open-minded teamwork spirit and state-of-the-art equipment, our integrated solution will help clients and partners to fulfil their research and development mission for cutting-edge and innovative nucleic acid drugs.Our service platforms include:nucleic acid drug discoveryscreening and preclinical research services of pharmacologyDMPK and toxicity study for both pharmaceutical companies and academic research institutions.The development of nucleic acid drugs is characterised by simple materials, convenient preparation processes and affordable production costs, which can greatly shorten the drug development cycle, making it possible to customize individual treatment plans. Hence, it offers a feasible solution for rare diseases and other problems currently plagued.Learn more:Medicilon nucleic acid drug R&D platform
With the development of bi-antibody technology, bi-antibody now presents a good development prospect. While major companies are deploying bi-antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of bi-antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers.Learn more:Antibody R&D Service Platform
Medicilon has provided comprehensive support and services for safety and effectiveness evaluation of various new drugs and vaccines establishing a complete bioanalysis platform for mRNA vaccines.Learn more:mRNA Vaccine Bioanalysis PlatformCell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. The rapid development of gene transduction and modification technology, delivery vector systems, cell culture technology and other fields, gene therapy provides a potential solutionto develop treatments to intractable diseases.Medicilon has established a one-stop research platform for the preclinical R&D of cell & gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, Medicilon has completed multiple preclinical projects for clients worldwide.
Medicilon relies on its strong drug innovation technology strength, integrates the company's internal superior resources, and joins forces among departments to build a platform for Medicilon's peptide drug conjugate (PDC) research and development into a technologically with advanced platform, complete supporting facilities and functions and standardized operation. It can form a comprehensive innovative drug research and development platform with integrated innovation capabilities, develop and provide key technologies, and can provide services such as the research and innovative peptide drugs, new peptide dosage forms, and peptide generic drugs.- Medicilon accelerates your drug development process.
20+ years of experience in new drug development
2000+ active clients worldwide
2600+ new drug R&D scientists and R&D service personnel
85000+ m2 Research and Development Laboratory
421+ INDs were successfully approved by FDA/NMPA/EMA and TGA
Drug Discovery Chemistry | Biology
Pharmaceutical Research API | Formulation
Preclinical Research Pharmacology | Pharmacokinetics | Safety Evaluation
IND Filing NMPA | TGA | FDA | EMA
